CO6361904A2 - Composiciones de dosis orales de liberación retardad que contienen bardoloxona-metilo (cddo-me) amorfo - Google Patents

Composiciones de dosis orales de liberación retardad que contienen bardoloxona-metilo (cddo-me) amorfo

Info

Publication number
CO6361904A2
CO6361904A2 CO11100847A CO11100847A CO6361904A2 CO 6361904 A2 CO6361904 A2 CO 6361904A2 CO 11100847 A CO11100847 A CO 11100847A CO 11100847 A CO11100847 A CO 11100847A CO 6361904 A2 CO6361904 A2 CO 6361904A2
Authority
CO
Colombia
Prior art keywords
methyl
bardoloxone
amorfo
cddo
compositions containing
Prior art date
Application number
CO11100847A
Other languages
English (en)
Inventor
Jiang Zhang
Colin J Meyer
Original Assignee
Reata Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42335073&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6361904(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Reata Pharmaceuticals Inc filed Critical Reata Pharmaceuticals Inc
Publication of CO6361904A2 publication Critical patent/CO6361904A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Las formulaciones farmacéuticas exhiben una Cmax deseablemente baja, entre otras propiedades, que contienen partículas de bardoxolona-metilo amorfo, ya sea en forma pura o en la forma de una dispersión sólida, mezcladas con partículas de un agente aglutinante hidrófilo. Estas formulaciones poseen la ventaja de mayor biodisponibilidad oral, con relación a las formulaciones basadas en la forma cristalina de bardoxolona-metilo.
CO11100847A 2009-02-13 2011-08-09 Composiciones de dosis orales de liberación retardad que contienen bardoloxona-metilo (cddo-me) amorfo CO6361904A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15260809P 2009-02-13 2009-02-13

Publications (1)

Publication Number Publication Date
CO6361904A2 true CO6361904A2 (es) 2012-01-20

Family

ID=42335073

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11100847A CO6361904A2 (es) 2009-02-13 2011-08-09 Composiciones de dosis orales de liberación retardad que contienen bardoloxona-metilo (cddo-me) amorfo

Country Status (29)

Country Link
US (2) US8747901B2 (es)
EP (2) EP3254675B1 (es)
JP (1) JP5775464B2 (es)
KR (2) KR101483203B1 (es)
CN (2) CN105232471A (es)
AU (1) AU2010213594B2 (es)
BR (1) BRPI1008023B8 (es)
CA (1) CA2752048C (es)
CO (1) CO6361904A2 (es)
CY (2) CY1119595T1 (es)
DK (2) DK3254675T3 (es)
EA (1) EA023652B1 (es)
ES (2) ES2646816T3 (es)
HK (1) HK1220130A1 (es)
HR (2) HRP20171639T1 (es)
HU (2) HUE044005T2 (es)
IL (1) IL214258A (es)
LT (2) LT2395979T (es)
MX (1) MX2011008344A (es)
MY (1) MY173715A (es)
NO (1) NO2395979T3 (es)
NZ (1) NZ594488A (es)
PL (2) PL2395979T3 (es)
PT (2) PT2395979T (es)
SG (1) SG173601A1 (es)
SI (2) SI3254675T1 (es)
TR (1) TR201909743T4 (es)
WO (1) WO2010093944A2 (es)
ZA (1) ZA201105630B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
RS58486B1 (sr) 2008-01-11 2019-04-30 Reata Pharmaceuticals Inc Sintetički triterpenoidi i metode njihove upotrebe u tretmanu bolesti
CN102164941B (zh) 2008-04-18 2015-05-27 里亚塔医药公司 抗氧化剂炎症调节剂:具有饱和c环的齐墩果酸衍生物
CN102066397B (zh) 2008-04-18 2013-09-11 里亚塔医药公司 包含抗炎症药效团的化合物以及使用方法
PL2276493T3 (pl) 2008-04-18 2019-05-31 Reata Pharmaceuticals Inc Antyoksydacyjne modulatory stanu zapalnego: pochodne kwasu oleanolowego z amino- i innymi modyfikacjami przy C-17
BRPI0911422B8 (pt) 2008-04-18 2021-05-25 Reata Pharmaceuticals Inc compostos moduladores inflamatórios antioxidantes, composição farmacêutica e usos dos mesmos
AU2009274037B2 (en) 2008-07-22 2015-07-09 Trustees Of Dartmouth College Monocyclic cyanoenones and methods of use thereof
KR101483203B1 (ko) 2009-02-13 2015-01-15 리아타 파마슈티컬즈, 아이엔씨. 무정형 ｃｄｄｏ-ｍｅ를 포함하는, 지연 방출형 경구 투여 조성물
ME03713B (me) 2010-04-12 2021-01-20 Reata Pharmaceuticals Inc Bardoksolon meтil za lečenje gojaznosтi
PL2651902T3 (pl) 2010-12-17 2018-04-30 Reata Pharmaceuticals, Inc. Pirazolilowe i pirymidynylowe tricykliczne enony jako modulatory zapalenia o działaniu przeciwutleniającym
UY33946A (es) 2011-03-11 2012-08-31 Reata Pharmaceuticals Inc Derivados de c4-monometil triterpenoides y sus métodos de uso
CN103156861B (zh) * 2011-12-08 2015-11-25 陈丽梅 齐敦果酸衍生物及其可药用盐在治疗糖尿病眼病中的应用
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
PT2841445T (pt) 2012-04-27 2017-09-01 Reata Pharmaceuticals Inc Derivados de 2,2-difluoropropionamida de metil bardoxolona, formas polimorfas e métodos de uso dos mesmos
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
US8981144B2 (en) 2012-05-08 2015-03-17 Trustees Of Dartmouth College Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof
WO2013188818A1 (en) 2012-06-15 2013-12-19 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
PE20150627A1 (es) 2012-09-10 2015-06-04 Reata Pharmaceuticals Inc Derivados de c17-alcandiilo y alquendiilo del acido oleanolico y sus metodos de uso
US9278912B2 (en) 2012-09-10 2016-03-08 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
TW201936625A (zh) 2013-04-24 2019-09-16 美商艾伯維有限公司 甲基巴多索龍之2,2-二氟丙醯胺衍生物、其多晶形及其使用方法
SG10201906113RA (en) 2013-08-23 2019-08-27 Reata Pharmaceuticals Inc Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
EP3212195A4 (en) 2014-10-31 2018-06-06 The Regents of The University of California Compositions and methods for treating hiv-associated cognitive dysfunction
JP6748652B2 (ja) 2015-02-12 2020-09-02 リアタ ファーマシューティカルズ インコーポレイテッド 抗酸化性炎症調節剤としてのイミダゾリル三環式エノン
EA201890767A1 (ru) 2015-09-23 2019-09-30 Рита Фармасьютикалз, Инк. C4-модифицированные производные олеаноловой кислоты для ингибирования il-17 и других применений
US10953020B2 (en) 2016-11-08 2021-03-23 Reata Pharmaceuticals, Inc. Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物
WO2019014412A1 (en) 2017-07-13 2019-01-17 Pliva Hrvatska D.O.O. NOVEL CRYSTALLINE POLYMORPHIC FORMS OF METHYL BARDOXOLONE
WO2019193488A1 (en) 2018-04-06 2019-10-10 Capsugel Belgium Nv Spray drying process for low aspect ratio particles comprising poly[(methyl methacrylate)-co-(methacrylic acid)]
CN112654610A (zh) 2018-06-15 2021-04-13 里亚塔医药公司 用于抑制IL-17和RORγ的吡唑和咪唑化合物
TW202038918A (zh) 2018-11-27 2020-11-01 日商協和麒麟股份有限公司 醫藥組合物
US20230255982A1 (en) 2020-05-09 2023-08-17 Reata Pharmaceuticals Holdings, LLC Methods of treating covid-19 using bardoxolone methyl or analogs thereof
EP4259155A1 (en) 2020-12-11 2023-10-18 Reata Pharmaceuticals Holdings, LLC Synthetic triterpenoids for use in therapy
CN114558019A (zh) * 2022-03-26 2022-05-31 中国科学院昆明动物研究所 一种Rab13基因抑制剂及应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US7435755B2 (en) * 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
JP2008110962A (ja) 2006-08-02 2008-05-15 Santen Pharmaceut Co Ltd Ｎｒｆ２活性化物質を有効成分として含む角結膜障害の予防または治療剤
JP4315182B2 (ja) * 2006-10-30 2009-08-19 ミツミ電機株式会社 カメラモジュール
WO2008111497A1 (ja) * 2007-03-08 2008-09-18 Santen Pharmaceutical Co., Ltd. トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
US8088824B2 (en) 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
RS58486B1 (sr) * 2008-01-11 2019-04-30 Reata Pharmaceuticals Inc Sintetički triterpenoidi i metode njihove upotrebe u tretmanu bolesti
KR101483203B1 (ko) 2009-02-13 2015-01-15 리아타 파마슈티컬즈, 아이엔씨. 무정형 ｃｄｄｏ-ｍｅ를 포함하는, 지연 방출형 경구 투여 조성물

Also Published As

Publication number Publication date
PL2395979T3 (pl) 2018-02-28
NO2395979T3 (es) 2018-01-20
WO2010093944A3 (en) 2011-08-11
ES2731601T3 (es) 2019-11-18
JP2012518008A (ja) 2012-08-09
US20120022156A1 (en) 2012-01-26
CY1119595T1 (el) 2018-03-07
PL3254675T3 (pl) 2019-09-30
LT2395979T (lt) 2017-12-11
KR20140016441A (ko) 2014-02-07
SI3254675T1 (sl) 2019-08-30
AU2010213594B2 (en) 2013-11-14
CA2752048C (en) 2014-11-25
BRPI1008023A2 (pt) 2016-03-15
EA023652B1 (ru) 2016-06-30
HRP20171639T1 (hr) 2017-12-15
MY173715A (en) 2020-02-18
LT3254675T (lt) 2019-06-25
CN105232471A (zh) 2016-01-13
DK2395979T3 (da) 2017-11-27
US20140235711A1 (en) 2014-08-21
ZA201105630B (en) 2012-04-25
EP3254675A1 (en) 2017-12-13
CN102387789A (zh) 2012-03-21
BRPI1008023B1 (pt) 2019-12-31
BRPI1008023B8 (pt) 2023-04-11
HK1220130A1 (zh) 2017-04-28
EP3254675B1 (en) 2019-05-15
SI2395979T1 (sl) 2017-12-29
HRP20191092T1 (hr) 2019-11-29
KR20110118721A (ko) 2011-10-31
EP2395979A2 (en) 2011-12-21
IL214258A0 (en) 2011-09-27
JP5775464B2 (ja) 2015-09-09
CY1122066T1 (el) 2020-11-25
ES2646816T3 (es) 2017-12-18
TR201909743T4 (tr) 2019-07-22
DK3254675T3 (da) 2019-06-24
HUE044005T2 (hu) 2019-09-30
US9155721B2 (en) 2015-10-13
EP2395979B1 (en) 2017-08-23
NZ594488A (en) 2013-10-25
EA201190092A1 (ru) 2012-02-28
CA2752048A1 (en) 2010-08-19
HUE035013T2 (en) 2018-05-02
PT2395979T (pt) 2017-11-16
MX2011008344A (es) 2011-09-29
AU2010213594A1 (en) 2011-08-18
PT3254675T (pt) 2019-06-14
IL214258A (en) 2017-06-29
KR101483203B1 (ko) 2015-01-15
US8747901B2 (en) 2014-06-10
SG173601A1 (en) 2011-09-29
WO2010093944A2 (en) 2010-08-19

Similar Documents

Publication Publication Date Title
CO6361904A2 (es) Composiciones de dosis orales de liberación retardad que contienen bardoloxona-metilo (cddo-me) amorfo
CO6680640A2 (es) Uso de aglutinantes para fabircar formulaciones estables al almacenamiento
CL2013001586A1 (es) Composicion microgranular de rapida dispersion que comprende al menos un alcohol de azucar, un sacarido, o una mezcla de estos, al menos un super disgregante y al menos un aditivo multifuncion; comprimido de desintegracion oral que comprende la composicion microgranular y al menos un principio activo; y metodos de fabricacion.
ECSP066715A (es)
CL2009001766A1 (es) Composicion farmaceutica solida para administracion oral que comprende: un taxano sustancialmente amorfo definido, un portador hidrofilico definido y un tensoactivo definido; metodo para preparar la composicion; y su uso para tratar una enfermedad neoplasica.
CR11709A (es) Preparacion solida de desintegracion oral
WO2011017502A3 (en) Linaclotide-containing formulations for oral administration
EP3626253A3 (en) Stable formulations of linaclotide
UY31788A (es) Formulación farmacéutica sólida con liberación retardada
MX2012013021A (es) Formulaciones resistentes a alcohol.
MY164204A (en) Formulations comprising polyethylene glycol
MX2010005198A (es) Composiciones liquidas que comprenden valsartan.
MY163476A (en) Oral care compositions
WO2011142731A3 (en) Formulations comprising a third generation cephalosporin and clavulanic acid
NI200700031A (es) Formulaciones de ácido hidroxamico suberoilanilida y procedimientos para la producción de las mismas
TR200909785A1 (tr) Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar.
WO2011090725A3 (en) Gastroretentive solid oral dosage forms with swellable hydrophilic polymer
TR201000689A1 (tr) Sefprozil içeren katı dozaj formlar.
CO6390098A2 (es) Formulaciones de desintegración rapida pre-compactadas de compuestos con baja biodisponibilidad oral.
CO6541608A2 (es) Formulación de empaque para evitar la insolubilidad de las composiciones que contienen quitosán
WO2013072770A3 (en) Pharmaceutical formulations comprising atorvastatin and glimepiride
WO2011066390A3 (en) Nanoscale adjuvants and related pharmaceutical compositions and methods
BR112014032033A2 (pt) formulações para a preparação de comprimidos de liberação imediata para administração oral contendo uma baixa dosagem de mifepristona, comprimidos desse modo obtidos e seu processo de preparação
TR200805337A2 (tr) Valsartan etkin maddesini içeren yeni oral farmasötik formülasyonlar
WO2011107922A3 (en) Extended release composition of milnacipran

Legal Events

Date Code Title Description
FC Application refused